ESMO 2019 | The value of PD-L1 as a biomarker beyond lung cancers

Name: The value of PD-L1 as a biomarker beyond lung cancers
Uploaded: 2019-09-27T00:00:00Z
Duration: 2 min 13 s
Description: Kevin Harrington, PhD, MBBS, Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, explains to us the value of PD-L1 as a biomarker, focusing on head and neck squamous cell carcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Kevin Harrington • 27 Sep 2019

ESMO 2019

Head and Neck Cancer Pembrolizumab

KEYNOTE-048

Kevin Harrington, PhD, MBBS, Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, explains to us the value of PD-L1 as a biomarker, focusing on head and neck squamous cell carcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.